The Business Research Company’s freshly released Evicel Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 offers a detailed look at a surgical hemostat that is quietly becoming indispensable in operating rooms worldwide. With demand fueled by everything from hemophilia caseloads to facelifts, the data points to sustained momentum for this plasma-derived fibrin sealant over the next decade.
Understanding the Evicel Market’s Growth and Dynamics
The Evicel market is advancing at a steady clip, propelled by clinical necessity and evolving surgical practice. As healthcare systems double down on patient safety and procedural efficiency, the appetite for reliable hemostatic agents such as Evicel continues to climb. The report breaks down current valuation, key growth levers, regional patterns, and the primary segments shaping the market’s future.
Exploring the Size and Growth Trajectory of the Evicel Market
Historically, the Evicel market has been buoyed by the serious risks of surgical bleeding, the shortcomings of mechanical compression methods, greater acceptance of plasma-derived biologics, a surge in complex operations, and a systemic push for better patient outcomes. Forward-looking projections point to sustained expansion driven by the uptake of minimally invasive techniques, rising surgical caseloads, growth in specialty clinics, progress in surgical biomaterials, and a persistent emphasis on operating room efficiency. Notable trends include wider intraoperative use of fibrin sealants, demand for biocompatible hemostats, an uptick in cardiovascular and hepatic procedures, preference for human plasma-based products, and refinement of advanced surgical methods.
Also worth a look: Lucentis market heads to $4.87M by 2030 as retinal disease cases climb and GiveDirectly uses USDC stablecoins to deliver earthquake cash aid to Venezuela.
Download a free sample of the evicel market report:
https://thebusinessresearchcompany.com/sample_request?id=96490121&type=smp&name=Evicel%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
The Role of Evicel in Surgical Hemostasis
Evicel is a fibrin sealant built from human fibrinogen and thrombin, designed to stanch bleeding and aid healing by accelerating clot formation during operations. It is routinely deployed in procedures where meticulous blood control is non-negotiable, including cardiovascular, liver, and orthopedic surgeries. Its biological compatibility reduces the likelihood of adverse reactions, positioning it as a safe choice for patients requiring precise intraoperative bleeding management.
Rising Prevalence of Bleeding Disorders Boosting Evicel Demand
A primary engine of market growth is the increasing frequency of bleeding disorders, which impair normal clot formation and can result in excessive or prolonged bleeding following injury or surgery. Genetic conditions such as hemophilia, lifestyle factors like poor nutrition and obesity, and chronic diseases that disrupt coagulation—liver disorders being a prime example—are all contributing to this trend. Evicel proves especially useful in managing hemorrhage for patients with clotting deficiencies. To illustrate, Pfizer Inc. reported in May 2025 that the hemophilia A and B patient population in the UK surpassed 11,800 individuals in 2023/2024. That growing patient base is expected to keep pushing Evicel demand upward.
View the full evicel market report:
https://thebusinessresearchcompany.com/report/evicel-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Impact of Chronic Diseases on the Expanding Evicel Market
The mounting burden of chronic illness is another major accelerant for the Evicel market. Conditions such as diabetes and heart disease—typically lasting a year or more and demanding ongoing care—often compromise patients’ healing and clotting capacity. Aging populations, unhealthy lifestyle patterns, environmental exposures, and better diagnostic detection all feed the rising incidence of these diseases. Evicel helps control bleeding and lower complication rates in surgical patients with chronic conditions. Data from the UK’s Office for Health Improvement & Disparities, published in March 2024, highlighted notable gains in diabetes care outcomes between 2022 and 2023—including a 22% increase in patients receiving all recommended care processes for type 1 diabetes and a 21% rise for type 2 diabetes. These developments underscore the expanding need for effective surgical hemostats like Evicel.
Increasing Popularity of Aesthetic Surgeries Driving Market Demand
Another significant growth driver is the soaring popularity of aesthetic procedures. These interventions—ranging from minimally invasive to non-invasive—are designed to enhance appearance by refining skin texture and diminishing signs of aging such as wrinkles and sagging. Higher disposable incomes, aging demographics, social media influence, and cosmetic technology breakthroughs are all fueling this boom. Evicel contributes by facilitating wound closure and reducing postoperative complications, which translates to less scarring and improved recovery. For example, the International Society of Aesthetic Plastic Surgery reported in June 2024 that total aesthetic procedures rose by 3.4% in 2023 to 34.9 million, with face and head procedures climbing nearly 20% to more than 6.5 million cases. This aesthetic surgery surge is having a tangible positive effect on the Evicel market.
Regional Insights Highlighting Evicel Market Trends
North America held the largest share of the Evicel market in 2025, underpinned by advanced healthcare infrastructure and swift adoption of innovative surgical products. The Asia-Pacific region, however, is forecast to be the fastest-growing market over the projection period. The report’s geographic coverage spans Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a thorough perspective on global market dynamics and opportunities.
The latest 2026 market reports from The Business Research Company come with expanded strategic and visual intelligence, including market attractiveness scoring and analysis, total addressable market (TAM) assessments, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+ +44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As surgical volumes climb and patient populations with coagulation challenges expand, the Evicel market’s trajectory reflects a broader shift toward biologic hemostatic solutions that improve safety and recovery. The sustained growth across regions signals that fibrin sealants will remain a critical tool in modern surgery, with implications for hospitals, device makers, and investors tracking the sector.
